NYU plans first annual Dual-Energy CT Symposium
NYU will hold its first annual Dual-Energy CT Symposium Oct. 9-10 in New York City. The program is designed for radiologists who have or are considering acquiring a dual-energy scanner, research scientists who are looking to understand current uses of dual-energy CT to stimulate development of translational research projects, and technologists who need a basis in dual-energy terminology and concepts.
NYU will hold its first annual Dual-Energy CT Symposium Oct. 9-10 in New York City. The program is designed for radiologists who have or are considering acquiring a dual-energy scanner, research scientists who are looking to understand current uses of dual-energy CT to stimulate development of translational research projects, and technologists who need a basis in dual-energy terminology and concepts.
Dual-energy CT (DECT) acquisition provides the radiologist with an expanded set of diagnostic capabilities and alters CT imaging in significant ways. Those who have worked with the technology believe it offers significant patient benefit for improved lesion detection, chemical analysis of normal and pathologic tissue, and iodine mapping. Perhaps most significantly, DECT may allow significant patient dose reduction by eliminating noncontrast scanning. Exciting research is currently under way to use the technology in novel ways to analyze treatment responses.
Directed by Dr. Alec J. Megibow, this one-and-a-half-day symposium will bring together clinical physics experts who are currently using both dual- and single-source technology. Attendees will benefit from learning how different approaches to DECT can be used to benefit patient care in all areas of the body. Emphasis will be placed on workflow, integration of DECT software into clinical image evaluation, and highlighting established indications and where research is heading.
To see the full program and register online, click here.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
